RECORD // Company

GRI Bio, Inc.

Formerly: Vallon Pharmaceuticals, Inc.

Built 2026-11-22T04:37:39Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Records under a former name (1)

The name on these records was this company's name in the past (SEC name history). An old name can also belong to an unrelated organization, so they are shown apart and are not counted above.

2 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-13 · accession 0001824293-26-000070

ItemValuePeriodFormFiledAccessionReport
Net income (loss)$-1,506,0003 months ended 2026-09-3010-Q2026-11-130001824293-26-0000702026-11-22 04:37 UTCReport an error
Cash and cash equivalents$9,472,000at 2026-09-3010-Q2026-11-130001824293-26-0000702026-11-22 04:37 UTCReport an error

Negative as reported in the filing.

Not in this report's XBRL: Revenue, Interest expense.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001824293
Ticker
GRI
EIN
824369909
CUSIP
3622AW502
Record ID
sx:sec:0001824293

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

31 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-13SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-13SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
State of incorporationDE2026-11-13SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
Fiscal year end (MMDD)12312026-11-13SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
Business address2223 AVENIDA DE LA PLAYA, SUITE 208, LA JOLLA, CA, 920372026-11-13SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
ExchangesNasdaq2026-11-13SEC EDGAR company profile2026-11-22 04:37 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-11,956,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 04:37 UTCReport an error
Total assets (at 2025-12-31)$8,666,0002025-12-3110-K, XBRL Assets2026-11-22 04:37 UTCReport an error
Stockholders' equity (at 2025-12-31)$6,008,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 04:37 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$8,229,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 04:37 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-10,186,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 04:37 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$3,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 04:37 UTCReport an error
Operating lease liabilities (at 2025-12-31)$71,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 04:37 UTCReport an error
Form D total offering amount (D filed 2024-10-25)$762,2362024-10-25D2026-11-22 04:37 UTCReport an error
Form D total amount sold (D filed 2024-10-25)$762,2362024-10-25D2026-11-22 04:37 UTCReport an error
Form D industry groupBiotechnology2024-10-25D2026-11-22 04:37 UTCReport an error
Form D revenue rangeDecline to Disclose2024-10-25D2026-11-22 04:37 UTCReport an error
Form D date of first sale2024-10-212024-10-25D2026-11-22 04:37 UTCReport an error
8-K Item 5.07, Submission of Matters to a Vote of Security Holders (filed 2026-11-04)The information set forth in Item 5.02 of this Current Report on Form 8-K is hereby incorporated by reference. Of the Company’s 2,186,115 shares of common stock issued and outstanding and eligible to vote as of the record date of September 22, 2026, a quorum of 926,474 shares, or approximately 42.37% of the eligible shares, was present in person or represented by proxy at the Annual Meeting. Each of the matters set forth below is described in detail in the Company’s Proxy Statement. The following actions were taken at the Annual Meeting: Proposal 1 Election of the following nominees to the Company's Board of Directors, each to serve as Class III directors until the Company’s 2029 Annual…2026-11-04SEC EDGAR 8-K 0001824293-26-000063 (text as filed, excerpt)2026-11-22 04:37 UTCReport an error
8-K Item 7.01, Regulation FD (filed 2026-09-08)On September 8, 2026, GRI Bio, Inc. (the "Company") posted an updated corporate presentation to the Company's website at www.gribio.com/investors/events-presentations/ which is included as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly…2026-09-08SEC EDGAR 8-K 0001824293-26-000057 (text as filed, excerpt)2026-11-22 04:37 UTCReport an error
8-K Item 8.01, Other Events (filed 2026-09-08)On September 8, 2026, the Company issued a press release announcing new translational biomarker data from the Phase 2a study evaluating GRI-0621 (oral tazarotene) in patients with idiopathic pulmonary fibrosis. The press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference.2026-09-08SEC EDGAR 8-K 0001824293-26-000057 (text as filed, excerpt)2026-11-22 04:37 UTCReport an error
Largest institutional holder #1 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$37,8212026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #2 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$24,5472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #3 (13F as filed): CITADEL ADVISORS LLC$23,6762026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #4 (13F as filed): UBS Group AG$8,7082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #5 (13F as filed): Tower Research Capital LLC (TRC)$4,3082026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #6 (13F as filed): BARCLAYS PLC$1472026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #7 (13F as filed): HRT FINANCIAL LP$502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #8 (13F as filed): BlackRock, Inc.$122026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #9 (13F as filed): Caitong International Asset Management Co., Ltd$42026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error
Largest institutional holder #10 (13F as filed): DANSKE BANK A/S$42026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 04:37 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.